Recovery Blueprint: Mifepristone Access and the FDA's Structural Authority Gap

The Structural Problem

The current dispute over mifepristone mail-order access exposes a fundamental design gap in federal drug regulation: the Food, Drug, and Cosmetic Act contains no explicit framework for post-approval judicial review of FDA scientific determinations. When the FDA approves a drug and later modifies its Risk Evaluation and Mitigation Strategy (REMS), opponents can challenge these determinations in federal court without triggering any statutory standard of review specific to pharmaceutical expertise. The result is not merely political controversy—it is structural incoherence. Courts are asked to evaluate complex pharmacological safety determinations without a clear mandate regarding deference, standing requirements, or the appropriate scope of review.

This case involves mifepristone, approved in 2000 and subject to multiple REMS modifications expanding access, including mail-order dispensing. Challengers argue the FDA acted arbitrarily in loosening restrictions. But the deeper problem is not whether courts should defer to the FDA—it is that the statutory architecture provides no definitive answer to that question. The Administrative Procedure Act offers only generic standards: "arbitrary and capricious" review. It does not account for the distinctive nature of pharmaceutical regulation, where safety determinations rest on evolving clinical data, post-market surveillance, and expert consensus that courts are institutionally ill-equipped to second-guess.

The mechanism failure is this: the FDA's scientific authority exists largely as an administrative custom, not as a judicially enforceable structural design. Congress has never codified the precise contours of post-approval review, the standing required to challenge REMS modifications, or the evidentiary standards courts must apply when reviewing agency pharmacological judgments. The result is a system vulnerable to litigation strategy rather than scientific process.

Root Cause: The Absence of a Pharmaceutical-Specific Judicial Review Framework

The Administrative Procedure Act was enacted in 1946, long before the modern pharmaceutical regulatory regime took shape. The FDA's drug approval process has evolved through decades of agency practice, court decisions, and incremental statutory amendments—but no comprehensive statute defines how courts should treat post-market modifications to approved drugs. The FDCA grants the FDA broad authority to approve drugs based on safety and efficacy, and to impose REMS when necessary. But it does not specify:

• What constitutes sufficient evidence to challenge a REMS modification years or decades post-approval
• Whether plaintiffs must demonstrate direct, individualized harm or whether generalized safety concerns suffice for standing
• Whether courts owe heightened deference to FDA scientific determinations compared to other agency actions

This is not a problem of bad faith. It is a problem of institutional underspecification. The design assumes the FDA's scientific judgments will be treated as presumptively valid, but that assumption is not encoded in binding structural terms. When litigants exploit this gap, courts are left improvising standards case-by-case, leading to inconsistent outcomes and institutional confusion.

Calibration 1: Amend the FDCA to Establish a Pharmaceutical-Specific Standard of Review

What it changes: Congress should amend 21 U.S.C. § 355 (the new drug approval provision) to add a new subsection specifying that post-approval modifications to REMS or distribution restrictions are subject to judicial review only if a challenger demonstrates with clear and convincing evidence that the FDA's determination was contrary to substantial clinical data available at the time of the modification. This creates a heightened evidentiary threshold specific to pharmaceutical safety judgments.

Who has authority: Congress, through ordinary legislation. The House Energy and Commerce Committee and the Senate Health, Education, Labor, and Pensions Committee have jurisdiction.

What it repairs: This Calibration replaces the generic "arbitrary and capricious" standard with a pharmaceutical-specific framework. It acknowledges that drug safety determinations are not like environmental or economic regulations—they rest on clinical evidence and expert interpretation. By requiring challengers to meet a "clear and convincing" standard and to point to substantial contrary clinical data, the statute would limit judicial second-guessing to cases where the FDA genuinely ignored significant scientific evidence, rather than merely made a policy choice within a range of reasonable expert disagreement.

Calibration 2: Codify Standing Requirements for Post-Approval Drug Challenges

What it changes: Congress should amend the FDCA to specify that standing to challenge a post-approval REMS modification requires the plaintiff to demonstrate either (a) direct prescribing or dispensing responsibility for the drug in question, combined with evidence of concrete regulatory burden, or (b) individualized patient harm causally linked to the modification. General objections to the FDA's safety conclusions would not suffice.

Who has authority: Congress, through the same legislative committees. Alternatively, the Supreme Court could adopt this standard as a matter of Article III standing doctrine, but statutory codification would provide greater clarity and durability.

What it repairs: This Calibration addresses the standing gap that allows parties with no direct connection to mifepristone prescribing or distribution to challenge FDA decisions. The current system permits ideological or associational plaintiffs to invoke generalized safety concerns as a basis for litigation. By requiring a concrete regulatory burden or individualized harm, the statute would ensure that challenges come from parties with actual operational knowledge and accountability—those who prescribe, dispense, or are directly affected by the drug's use. This filters out litigation driven purely by disagreement with FDA policy, rather than by evidence of regulatory failure.

Calibration 3: Establish an Expert Panel Review Process Before Judicial Intervention

What it changes: The FDCA should be amended to require that any legal challenge to a post-approval REMS modification first be reviewed by an independent expert panel convened by the National Academies of Sciences, Engineering, and Medicine. The panel would assess whether the FDA's determination falls within the range of scientifically defensible judgments. Only if the panel finds the FDA's decision indefensible may a lawsuit proceed. The panel's findings would be part of the administrative record.

Who has authority: Congress, by statute. The FDA would implement the process administratively, contracting with the National Academies or a similar body.

What it repairs: This Calibration inserts a scientific filter before judicial review. Courts are not structured to evaluate complex pharmacological evidence, but expert panels are. By requiring preliminary expert review, the system ensures that only cases involving genuine scientific outliers reach the judiciary. This does not insulate the FDA from accountability—it channels accountability through scientifically competent bodies before subjecting the agency to judicial scrutiny. It also creates a clear record for courts, who can defer to expert consensus rather than attempting de novo evaluation of clinical data.

Feasibility Assessment

Of the three Calibrations, Calibration 2 (standing requirements) is the most achievable in the near term. It requires no fundamental restructuring of the FDA or the judicial system—only a clarification of who may bring suit. It could be included in routine FDA reauthorization legislation or attached to budget reconciliation measures affecting healthcare. It would immediately reduce the volume of ideological challenges and focus litigation on parties with operational stakes.

Calibration 1 (heightened standard of review) would face resistance from those concerned about limiting judicial oversight, but it represents a necessary repair if the FDA's scientific authority is to remain structurally coherent. Without it, every REMS modification will remain vulnerable to litigation refighting decades-old approval decisions.

Calibration 3 (expert panel review) is the most ambitious and faces implementation challenges, but it offers the most robust long-term solution by aligning institutional competencies: experts evaluate science, courts evaluate legal procedure.

The minimum repair needed to prevent cascade failure is Calibration 2. Without standing limits, the FDA will face continuous litigation over every incremental policy adjustment, eroding the agency's practical authority and creating regulatory paralysis. The mifepristone case is not an isolated incident—it is a preview of what occurs when structural underspecification meets determined litigants. The system can be repaired, but only if Congress acts to encode the institutional boundaries that administrative custom alone cannot sustain.